Patent · US Active

β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment

US10815266B2 · kind B2 · utility

4Cited by

176References

2Claims

0Family size

Assignee

Atea Pharmaceuticals, Inc. · US

Inventors

Jean-Pierre Sommadossi · Cambridge, US
Adel Moussa · Burlington, US

Key dates

Filing date	Feb 18, 2019
Grant date	Oct 27, 2020
Priority date	—
Expiry date	Feb 18, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07H19/20
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A compound of the structure: or a pharmaceutically acceptable salt or composition thereof for the treatment of a host infected with or exposed to an HCV virus or other disorders more fully described herein.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.